$CNTA
Centessa Pharmaceuticals plc

2021 Q4 Form 10-Q Financial Statement

#000184790321000025 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2021 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.99M $12.46M $17.44M
YoY Change 4116.88% 6358.03% 6606.15%
% of Gross Profit
Research & Development $41.53M $25.85M $18.13M
YoY Change 1440.01% 1244.25% 869.21%
% of Gross Profit
Depreciation & Amortization $12.00K $15.74K $5.434K
YoY Change
% of Gross Profit
Operating Expenses $58.29M $25.85M $18.13M
YoY Change 1839.83% 1244.25% 869.21%
Operating Profit -$38.31M -$41.29M
YoY Change 1710.68% 1839.27%
Interest Expense -$1.272M $65.00K $27.00K
YoY Change 542.42% -395.45% -258.82%
% of Operating Profit
Other Income/Expense, Net -$1.096M -$1.906M -$191.0K
YoY Change 1189.41% -31866.67% 1810.0%
Pretax Income -$60.66M -$40.16M -$280.1M
YoY Change 1746.01% 1778.16% 12462.42%
Income Tax $114.0K $0.00
% Of Pretax Income
Net Earnings -$60.77M -$40.16M -$41.45M
YoY Change 469.95% 1778.16% 1760.46%
Net Earnings / Revenue
Basic Earnings Per Share -$0.45 -$0.65
Diluted Earnings Per Share -$661.5K -$0.45 -$0.65
COMMON SHARES
Basic Shares Outstanding 89.90M shares 89.90M shares 63.52M shares
Diluted Shares Outstanding 89.90M shares 63.52M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $595.1M $578.8M $613.8M
YoY Change
Cash & Equivalents $595.1M $578.8M $613.8M
Short-Term Investments
Other Short-Term Assets $993.0K $1.050M $444.0K
YoY Change 16450.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $628.8M $611.6M $643.7M
YoY Change 5531.65%
LONG-TERM ASSETS
Property, Plant & Equipment $162.0K $114.0K $74.80K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $699.0K $448.0K
YoY Change 26.63%
Total Long-Term Assets $861.0K $562.0K $75.00K
YoY Change 55.98%
TOTAL ASSETS
Total Short-Term Assets $628.8M $611.6M $643.7M
Total Long-Term Assets $861.0K $562.0K $75.00K
Total Assets $629.6M $612.2M $643.8M
YoY Change 5273.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.065M $18.46M $7.261M
YoY Change 681.49%
Accrued Expenses $16.57M $10.69M $16.92M
YoY Change 1482.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $0.00
YoY Change
Total Short-Term Liabilities $24.64M $29.14M $24.19M
YoY Change 185.86%
LONG-TERM LIABILITIES
Long-Term Debt $75.70M $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.00K $33.93M $33.93M
YoY Change
Total Long-Term Liabilities $75.74M $33.93M $33.93M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $24.64M $29.14M $24.19M
Total Long-Term Liabilities $75.74M $33.93M $33.93M
Total Liabilities $138.1M $63.07M $58.12M
YoY Change 1502.05%
SHAREHOLDERS EQUITY
Retained Earnings -$385.7M -$324.9M -$284.7M
YoY Change
Common Stock $252.0K $252.0K $252.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $491.6M $549.1M $585.6M
YoY Change
Total Liabilities & Shareholders Equity $629.6M $612.2M $643.8M
YoY Change 5273.69%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2021 Q2
OPERATING ACTIVITIES
Net Income -$60.77M -$40.16M -$41.45M
YoY Change 469.95% 1778.16% 1760.46%
Depreciation, Depletion And Amortization $12.00K $15.74K $5.434K
YoY Change
Cash From Operating Activities -$56.43M -$32.18M -$33.88M
YoY Change 1619.81% 767.47% 1771.66%
INVESTING ACTIVITIES
Capital Expenditures -$64.00K -$48.00K -$37.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 -$112.0K
YoY Change
Cash From Investing Activities -$64.00K -$48.00K -$149.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 74.43M -1.992M 345.8M
YoY Change 5692.14% -2687.01%
NET CHANGE
Cash From Operating Activities -56.43M -32.18M -33.88M
Cash From Investing Activities -64.00K -48.00K -149.0K
Cash From Financing Activities 74.43M -1.992M 345.8M
Net Change In Cash 17.94M -34.22M 311.8M
YoY Change -998.7% 842.0% -17326.24%
FREE CASH FLOW
Cash From Operating Activities -$56.43M -$32.18M -$33.88M
Capital Expenditures -$64.00K -$48.00K -$37.00K
Free Cash Flow -$56.36M -$32.14M -$33.84M
YoY Change 766.17% 1769.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001847903
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-04321
dei Entity Registrant Name
EntityRegistrantName
CENTESSA PHARMACEUTICALS PLC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
X0
dei Entity Address Address Line1
EntityAddressAddressLine1
3rd Floor
dei Entity Address Address Line2
EntityAddressAddressLine2
1 Ashley Road
dei Entity Address Address Line3
EntityAddressAddressLine3
Altrincham
dei Entity Address City Or Town
EntityAddressCityOrTown
Cheshire
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
WA14 2DT
dei Entity Address Country
EntityAddressCountry
GB
dei Country Region
CountryRegion
+44
dei City Area Code
CityAreaCode
7391
dei Local Phone Number
LocalPhoneNumber
789784
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89900916 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
578815000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7227000 USD
CY2021Q3 cnta Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
18611000 USD
CY2020Q4 cnta Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
2633000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14219000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1305000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
611645000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
11165000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2021Q3 cnta Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
0 USD
CY2020Q4 cnta Tax Incentive Receivable Noncurrent
TaxIncentiveReceivableNoncurrent
552000 USD
CY2021Q3 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
448000 USD
CY2020Q4 us-gaap Deferred Finance Costs Noncurrent Net
DeferredFinanceCostsNoncurrentNet
0 USD
CY2021Q3 us-gaap Assets
Assets
612207000 USD
CY2020Q4 us-gaap Assets
Assets
11717000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
18456000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1032000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10688000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1047000 USD
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2020Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
5339000 USD
CY2021Q3 us-gaap Loans Payable Current
LoansPayableCurrent
0 USD
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
288000 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 USD
CY2020Q4 us-gaap Liabilities
Liabilities
8619000 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
913000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29144000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8619000 USD
CY2021Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
33930000 USD
CY2020Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities
Liabilities
63074000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2021Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2021Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
6549205 shares
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6549205 shares
CY2021Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0 USD
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
25521000 USD
CY2020Q4 us-gaap Members Equity
MembersEquity
-22423000 USD
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.002
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
22840902 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
89900425 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89900425 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89900425 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
0 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
252000 USD
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
871022000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2738000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324879000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
549133000 USD
CY2020Q4 cnta Members Equity And Temporary Equity Carrying Amount Attributable To Parent
MembersEquityAndTemporaryEquityCarryingAmountAttributableToParent
3098000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
612207000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11717000 USD
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25850000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
54126000 USD
CY2021Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
600000 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1923000 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6604000 USD
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12464000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
29900000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
121000 USD
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
193000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
831000 USD
CY2021Q3 cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
11312000 USD
CY2021Q1 cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
CY2020Q3 cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
CY2021Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
220454000 USD
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2020Q3 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-38314000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-315792000 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-721000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2116000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7435000 USD
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
65000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
100000 USD
CY2021Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-9000 USD
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-22000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-56000 USD
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
37000 USD
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
78000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
220000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1906000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4605000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5000 USD
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
72000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
339000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-40155000 USD
us-gaap Net Income Loss
NetIncomeLoss
-320297000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-767000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2138000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7377000 USD
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-487000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2828000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7736000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
45000 USD
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
372000 USD
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-359000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40642000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-317469000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-722000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1766000 USD
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.60
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.60
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
89899454 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
89899454 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69597648 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69597648 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-4651000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3403000 USD
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
241597000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
6250000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
262698000 USD
CY2021Q1 cnta Adjustments To Additional Paid In Capital Forgiveness Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalForgivenessOfConvertibleDebt
6199000 USD
CY2021Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
12000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
292000 USD
CY2021Q1 cnta Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Aggregate Intrinsic Value Vested
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsAggregateIntrinsicValueVested
0 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2731000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2221000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-238691000 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
278634000 USD
CY2021Q2 cnta Stock Issued During Period Value Conversion Of Convertible Preferred Stock
StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock
0 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8800000 USD
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3229000 USD
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1094000 USD
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-41451000 USD
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
585642000 USD
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4133000 USD
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-487000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-40155000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
549133000 USD
CY2020Q4 us-gaap Members Equity
MembersEquity
-22423000 USD
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
45000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-767000 USD
CY2021Q1 us-gaap Members Equity
MembersEquity
-23145000 USD
CY2019Q4 us-gaap Members Equity
MembersEquity
-11857000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
63000 USD
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-707000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3011000 USD
CY2020Q1 us-gaap Members Equity
MembersEquity
-15512000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
153000 USD
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-25000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-2228000 USD
CY2020Q2 us-gaap Members Equity
MembersEquity
-17612000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
29000 USD
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
372000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2138000 USD
CY2020Q3 us-gaap Members Equity
MembersEquity
-19349000 USD
us-gaap Net Income Loss
NetIncomeLoss
-320297000 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-767000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7377000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
220454000 USD
CY2021Q1 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
10093000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
245000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 USD
cnta Noncash Interest Income Expense
NoncashInterestIncomeExpense
0 USD
CY2021Q1 cnta Noncash Interest Income Expense
NoncashInterestIncomeExpense
-9000 USD
cnta Noncash Interest Income Expense
NoncashInterestIncomeExpense
-32000 USD
cnta Amortization Of Unpaid Do Insurance Premiums
AmortizationOfUnpaidDOInsurancePremiums
2972000 USD
CY2021Q1 cnta Amortization Of Unpaid Do Insurance Premiums
AmortizationOfUnpaidDOInsurancePremiums
0 USD
cnta Amortization Of Unpaid Do Insurance Premiums
AmortizationOfUnpaidDOInsurancePremiums
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
37000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
220000 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
339000 USD
cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
11312000 USD
CY2021Q1 cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
cnta Asset Acquisition Contingent Consideration Liability Gain Loss From Change In Fair Value
AssetAcquisitionContingentConsiderationLiabilityGainLossFromChangeInFairValue
0 USD
cnta Increase Decrease In Tax Incentive Receivables
IncreaseDecreaseInTaxIncentiveReceivables
10253000 USD
CY2021Q1 cnta Increase Decrease In Tax Incentive Receivables
IncreaseDecreaseInTaxIncentiveReceivables
-74000 USD
cnta Increase Decrease In Tax Incentive Receivables
IncreaseDecreaseInTaxIncentiveReceivables
948000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6149000 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-681000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-891000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5529000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-358000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-42000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7635000 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-589000 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-31000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78682000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-987000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7349000 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
68038000 USD
CY2021Q1 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
4596000 USD
CY2021Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 USD
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
63320000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
241597000 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
344136000 USD
CY2021Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
12000 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2021Q1 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
295000 USD
CY2021Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
292000 USD
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
77000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
585718000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
77000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3493000 USD
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18000 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-430000 USD
CY2021Q2 cnta Sale Of Stock Number Of Ordinary Shares Per American Depositary Shares
SaleOfStockNumberOfOrdinarySharesPerAmericanDepositaryShares
1 shares
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.002
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
578815000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6258000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
573849000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-969000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7702000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4966000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7227000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16570000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8868000 USD
us-gaap Stock Issued1
StockIssued1
262698000 USD
CY2021Q1 us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
0 USD
cnta Contingent Value Rights Issued
ContingentValueRightsIssued
22618000 USD
CY2021Q1 cnta Contingent Value Rights Issued
ContingentValueRightsIssued
USD
cnta Contingent Value Rights Issued
ContingentValueRightsIssued
USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
6250000 USD
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
6199000 USD
CY2021Q1 us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0 USD
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
0 USD
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
12000 USD
CY2021Q1 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0 USD
us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
0 USD
cnta Debt Issuance Costs Incurred But Not Yet Paid
DebtIssuanceCostsIncurredButNotYetPaid
448000 USD
CY2021Q1 cnta Debt Issuance Costs Incurred But Not Yet Paid
DebtIssuanceCostsIncurredButNotYetPaid
0 USD
cnta Debt Issuance Costs Incurred But Not Yet Paid
DebtIssuanceCostsIncurredButNotYetPaid
0 USD
CY2021Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
344100000 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324900000 USD
cnta Cash And Cash Equivalents At Carrying Value Sufficient Funding Term
CashAndCashEquivalentsAtCarryingValueSufficientFundingTerm
P12M
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
578800000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on previously reported net loss or comprehensive loss.</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of unaudited interim financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited interim consolidated and combined financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the unaudited interim consolidated and combined financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include share-based compensation assumptions, derivative liability and contingent value rights assumptions, accrued research and development expenses, and, prior to the IPO, the fair value of the Company’s ordinary shares.</span></div>
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
114000 USD
CY2021Q3 us-gaap Depreciation
Depreciation
15744 USD
us-gaap Depreciation
Depreciation
22551 USD
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11742566 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11742566 shares
CY2021Q3 us-gaap Prepaid Insurance
PrepaidInsurance
7995000 USD
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
9000 USD
CY2021Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
2945000 USD
CY2020Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
298000 USD
CY2021Q3 cnta Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
2229000 USD
CY2020Q4 cnta Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
992000 USD
CY2021Q3 us-gaap Other Assets Current
OtherAssetsCurrent
1050000 USD
CY2020Q4 us-gaap Other Assets Current
OtherAssetsCurrent
6000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14219000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1305000 USD
CY2021Q3 cnta Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
5194000 USD
CY2020Q4 cnta Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1001000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10688000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1047000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2936000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
0 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2324000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
37000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
234000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9000 USD
CY2020Q4 us-gaap Members Equity
MembersEquity
-22423000 USD
cnta Debt Instrument Convertible Conversion Price Discount Percentage Next Qualified Fundraising
DebtInstrumentConvertibleConversionPriceDiscountPercentageNextQualifiedFundraising
0.20
cnta Debt Instrument Convertible Conversion Price Discount Percentage Change In Control
DebtInstrumentConvertibleConversionPriceDiscountPercentageChangeInControl
0.50
CY2021Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
700000 USD
cnta Adjustments To Additional Paid In Capital Forgiveness Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalForgivenessOfConvertibleDebt
6200000 USD
CY2021Q3 us-gaap Purchase Obligation
PurchaseObligation
17100000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
15900000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Second And Third Year
PurchaseObligationDueInSecondAndThirdYear
1200000 USD
CY2021Q3 cnta Common Stock Number Of Votes Ratio
CommonStockNumberOfVotesRatio
1
CY2021Q1 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
4450000 shares
us-gaap Preferred Stock Dividends Per Share Declared
PreferredStockDividendsPerShareDeclared
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4133000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10093000 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
245000 USD
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
19192910 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8437705 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11792647 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.36
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
987442 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.29
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10755205 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.47
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3M18D
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
574267 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.66
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.47
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
43000000 USD
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
101900000 USD
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7000000 USD
CY2015Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.74
CY2015Q4 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.74
CY2021Q3 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.74
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.86
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.86
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.86
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.86
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.74
CY2019Q1 us-gaap Foreign Currency Exchange Rate Translation1
ForeignCurrencyExchangeRateTranslation1
0.74

Files In Submission

Name View Source Status
0001847903-21-000025-index-headers.html Edgar Link pending
0001847903-21-000025-index.html Edgar Link pending
0001847903-21-000025.txt Edgar Link pending
0001847903-21-000025-xbrl.zip Edgar Link pending
a20210930exhibit101.htm Edgar Link pending
a20210930exhibit311.htm Edgar Link pending
a20210930exhibit312.htm Edgar Link pending
a20210930exhibit321.htm Edgar Link pending
a20210930exhibit322.htm Edgar Link pending
cnta-20210930.htm Edgar Link pending
cnta-20210930.xsd Edgar Link pending
cnta-20210930_cal.xml Edgar Link unprocessable
cnta-20210930_def.xml Edgar Link unprocessable
cnta-20210930_htm.xml Edgar Link completed
cnta-20210930_lab.xml Edgar Link unprocessable
cnta-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending